Evaluation of the Short and Long Term Performance and Clinical Outcomes of the Crux Vena Cava Filter System
NCT02420626 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2016-04-22
Summary
The Crux Vena Cava Filter (VCF) Registry is a clinical study, sponsored by Volcano Corporation, to evaluate the short and long term performance and clinical outcomes of the Crux Vena Cava Filter System.
Conditions
- Pulmonary Embolism
- Venous Thromboembolism
- Deep Vein Thrombosis
Sponsors & Collaborators
-
Volcano Corporation
lead INDUSTRY
Eligibility
- Min Age
- 19 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-01-31
- Primary Completion
- 2017-05-31
- Completion
- 2019-05-31
Countries
- United States
Study Locations
More Related Trials
-
Single Center Post-Market Study of Thrombolytic Therapy Using the Versus™ Catheter
NCT06975969 ·Status: WITHDRAWN
-
Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters
NCT04066764 ·Status: RECRUITING ·Phase: PHASE3
-
Risk Factors for Venous Thromboembolism in the Community
NCT00011180 ·Status: COMPLETED
-
Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients
NCT00493896 ·Status: TERMINATED ·Phase: PHASE3
-
Risk Stratification for Venous Thromboembolism in Hospitalized Medical Patients
NCT04439383 ·Status: COMPLETED
-
Safety and Efficacy Study of Fitaya Vena Cava Filter
NCT03691753 ·Status: UNKNOWN ·Phase: NA
-
Impact of Continuous Veno-venous Hemodiafiltration on Efficacy of Administration of Prophylactic Doses of Enoxaparin or Fondaparinux in Critically Ill Patients.
NCT04671160 ·Status: UNKNOWN
-
In Vivo Detection of Circulating Clots in Patients With Thromboembolism
NCT05301348 ·Status: RECRUITING ·Phase: NA
-
Risk of Recurrent Venous Thromboembolism After Provoked Venous Thromboembolism
NCT04124159 ·Status: UNKNOWN
-
Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin Dose
NCT02704052 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Immature Plateletes in the Etiopathology of Deep Venous Thrombosis
NCT02361294 ·Status: COMPLETED
-
Understanding Risk Factors Involved in Developing a Second Blood Clot.
NCT00261014 ·Status: UNKNOWN
-
VTEval Project - Prospective Cohort Studies to Evaluate and Improve Diagnostics, Management Strategies and Risk Stratification in VTE
NCT02156401 ·Status: RECRUITING
-
Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients
NCT00521885 ·Status: TERMINATED ·Phase: NA
-
CAPERE Thrombectomy System Post-Market Clinical Follow Up Study
NCT03869645 ·Status: TERMINATED
-
Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery
NCT01444612 ·Status: COMPLETED
-
Retrospective Study to Review Patients at Risk for VTE at Hospital Discharge
NCT00604370 ·Status: COMPLETED
-
Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters
NCT00024297 ·Status: COMPLETED ·Phase: NA
-
The Risk of Venous Clotting in Patients After Renal Transplant
NCT01413464 ·Status: UNKNOWN
-
Risk Factors and Prediction Model of Cancer-associated Venous Thromboembolism
NCT05729464 ·Status: UNKNOWN
-
Microvesicle Production After Acute Trauma and Its Clinical Impact on Venothromboembolism
NCT01264458 ·Status: COMPLETED
-
Thromboprophylaxis of Venous Thromboembolism in Acutely-ill Medical Inpatients With Thrombocytopenia
NCT01727401 ·Status: TERMINATED ·Phase: PHASE4
-
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
NCT02744092 ·Status: COMPLETED ·Phase: NA
-
Treatment for Blood Clots in the Veins of the Legs
NCT00001713 ·Status: COMPLETED ·Phase: PHASE1
-
The Catheter Study: Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis
NCT00216866 ·Status: COMPLETED ·Phase: PHASE2